Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05185505 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

StatusEnrolling by Invitation
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status changed: Recruiting → Enrolling by Invitation Completion pushed from Oct 31, 2027 to Oct 31, 2028 · Study sites: 1 to 2 · Eligibility criteria expanded, about 125 words · 3 more Show 6 more changesShow less
    • Completion pushed from Oct 31, 2027 to Oct 31, 2028
    • Study sites: 1 to 2
    • Eligibility criteria expanded, about 125 words
    • Secondary endpoints: 9 to 10
    • Study description shortened, about 1,513 words
    • Publications: details revised at 25 of 29 entries
  2. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Jun 17, 2026 to Apr 30, 2027 · Start date changed from estimate of Mar 17, 2022 to Jan 30, 2023 · Completion date: Dec 17, 2026 to Oct 31, 2027 · 1 morev2 Show 4 more changesShow less
    • Primary completion date: Jun 17, 2026 to Apr 30, 2027
    • Start date changed from estimate of Mar 17, 2022 to Jan 30, 2023
    • Completion date: Dec 17, 2026 to Oct 31, 2027
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are undergoing evaluation for or waitlisted for liver transplantation will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolization (TACE) or transarterial radioembolization (TARE). We hypothesize that atezolizumab and bevacizumab can appropriately bridge patients with HCC beyond MC to transplantation and not increase the risk of 1-year post-transplant rejection.
Trial Details
NCT Number NCT05185505
Lead Sponsor The Methodist Hospital Research Institute
Collaborators: Genentech, Inc.
Conditions Hepatocellular Carcinoma, Hepatocellular Cancer
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov